Abstract
Background and aimsChronic hepatitis B (CHB) disproportionately affects the Asian-American population in the USA. Tenofovir disoproxil fumarate (TDF) has demonstrated potent antiviral activity in clinical trials, but data in Asian-Americans from community studies are lacking.MethodsAdult Asian-American patients with CHB from private medical and community-based practices were prospectively enrolled and treated with open-label TDF 300 mg once daily in a single-arm study for 48 weeks. After Week 48, patients had the option to transition to commercially available CHB therapy. The primary efficacy endpoint was hepatitis B virus (HBV) DNA <400 copies/mL at Week 48. Secondary endpoints were safety and tolerability, serologic and biochemical responses, liver fibrosis by FibroTest, and the development of drug-resistant mutations.ResultsOf the 90 patients enrolled, 53 (58%) were hepatitis B e antigen (HBeAg)-positive at baseline. At Week 48, 74 patients (82% overall; 70% HBeAg-positive and 100% HBeAg-negative) had HBV DNA <400 copies/mL. Six (12%) HBeAg-positive patients achieved HBeAg loss/seroconversion. The percentage of patients with alanine aminotransferase in the normal range increased from 26% at baseline to 66% at Week 48. The percentage of patients with F0 (no or minimal) fibrosis by FibroTest increased from 48% to 51%, and those with F4 (severe) fibrosis decreased from 4% to 1%. No resistance to TDF developed. Treatment was well tolerated. Most adverse events were mild in severity and considered unrelated to study drug.ConclusionsTDF is effective and well tolerated in Asian-American CHB patients in community clinic-based settings, consistent with larger registration trials. Improvement in liver fibrosis was seen in a proportion of patients. No resistance to TDF developed through 48 weeks of treatment.Trial RegistrationClinicaltrial.gov identifier NCT00736190
Highlights
Chronic hepatitis B infection (CHB) is a serious public health challenge among Asians and Pacific Islanders residing in the United States
Comprising only 4.3% of the overall population, Asian-Americans make up half of the estimated 2 million Americans living with CHB, [1] with a reported prevalence of up to 15% depending on the sample population
CHB-related hepatocellular carcinoma (HCC) has become the most important cancer health disparity affecting AsianAmericans and similar statistics are increasingly being reported in other Western countries [5]
Summary
Chronic hepatitis B infection (CHB) is a serious public health challenge among Asians and Pacific Islanders residing in the United States. CHB-related hepatocellular carcinoma (HCC) has become the most important cancer health disparity affecting AsianAmericans and similar statistics are increasingly being reported in other Western countries [5]. The goal of therapy for CHB is to maintain suppression of viral replication to prevent the emergence of complications, such as cirrhosis, decompensated liver disease, and HCC [7,8]. Effective suppression of viral replication alters the course of CHB, reducing the histological activity, lessening the risk of progressive liver disease and the HCC incidence [9,10,11]. Chronic hepatitis B (CHB) disproportionately affects the Asian-American population in the USA. Tenofovir disoproxil fumarate (TDF) has demonstrated potent antiviral activity in clinical trials, but data in Asian-Americans from community studies are lacking
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
